Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00000809

Enrollment

Registered

2001-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, HIV Seronegativity

Keywords

HIV Preventive Vaccine, HIV Therapeutic Vaccine

Brief summary

The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.

Interventions

BIOLOGICALAluminum hydroxide

BIOLOGICALQS-21

BIOLOGICALMN rsgp120/HIV-1

Study design

Primary purpose

PREVENTION

Eligibility

Sex/Gender

ALL

Age

1 Days to 3 Days

Healthy volunteers

Yes

Inclusion criteria

Infants may be eligible for this study if they: * Are 1 to 3 days old.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026